Medical Lymphatic Animation

Lymphoma Association Launches New Short Film
The Lymphoma Association is delighted to launch their latest short film which shows the services they offer to anyone affected by lymphoma - the UK's sixth most common cancer. The charity were selected to have the film made for them for a nominal fee by the Media Trust, an organisation which helps charities raise awareness by providing them with volunteers from the TV, film and video industry who then produce videos for them.

High Dose Chemotherapy Significantly Prolongs Survival For Patients With Acute Myeloid Leukemia
Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia (AML), a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug. Daunorubicin, a drug originally approved for use by the U.S.

Cold/Flu Breakthrough Remedy Undergoes NCI-Sponsored Trial In Leukemia Patients: Canada
Cancer patients - with their weakened immune systems - are particularly vulnerable when the cold and flu season hits. To help, the U.S. National Cancer Institute (NCI) is sponsoring a landmark trial to see whether a unique Canadian cold remedy - COLD-FX - can help.

Researchers Tackle CLL, Diabetes And Trauma-Hemorrhage - Molecular Medicine, A Bi-Monthly Journal
Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. In this month's issue of

The Genetics Of Aging And Cancer Resistance
In the November 15th issue of G&D, Dr. Kenneth Dorshkind and colleagues at the David Geffen School of Medicine (UCLA) have identified two genes - p16(Ink4a) and Arf - that sensitize lymphoid progenitor cells to the effects of aging, and confer resistance to leukemogenesis. Hematopoiesis (the development of blood cells) entails two main pathways: myelopoiesis (the formation of the red and white myeloid cells) and lymphopoiesis (the formation of B- and T-cells).

Case Of Patient "Cured" Of HIV Baffles Doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia.

INNO-406 Demonstrates Positive Clinical Responses In Phase 1 Trial In Patients With Chronic Myeloid Leukemia
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful In Achieving Primary Endpoint
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis.

Researchers Aim To Over-stress Already Taxed Mantle Cell Lymphoma Cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them. "Think about an assembly line in a factory that is working five times faster than normal," said Dr. Kapil Bhalla, director of the Medical College of Georgia Cancer Center. "There is a lot of stress but you need workers to keep going. Some of them fall out, some get bent out of shape.

Genmab A/S: Ofatumumab Pivotal CLL Data To Be Presented At ASH
Genmab A/S (OMX: GEN) announced that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session.

National Gala Raises Over $1.15 Million For Lymphoma-Focused Research - Guests Vote To Eradicate Lymphoma
Over 520 guests reached into their pockets to the tune of over $1.15 million and cast their vote for increased funding for lymphoma-focused research at Vote For A Cure: the Lymphoma Research Foundation's (LRF) 2008 National Gala held on October 6 at the New York Marriot Marquis. Tom Brokaw, NBC News, shared emcee duties with Jeff Greenfield of CBS News for this very successful event.

All Patients Should Have Access To The Novel Therapies For Myeloma, Says International Myeloma Foundation
The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma.

CIGNA To Promote The Leukemia & Lymphoma Society's Co-Pay Assistance Program, USA
CIGNA Pharmacy Management (CIGNA) and the Leukemia & Lymphoma Society (LLS) are joining forces to promote LLS's efforts to help blood cancer patients cover the costs of prescription co-pays and health insurance premiums. The costs of cancer are significant. According to the National Cancer Institute, direct medical costs for cancer care in 2004 totaled more than $72 billion.

Researchers Find Predictive Tests And Early Treatment Delay Progression Of Blood Cell Cancer
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL). Their study, published Oct.

Tackling Hard-to-treat Childhood Cancer By Targeting Epigenetic Changes
A very difficult-to-treat child leukemia may benefit from the discovery of a small but potent epigenetic change that launches the cancer - but could potentially be reversed relatively easily, preventing cancer-promoting genes from being turned on. The study, led by researchers at Children's Hospital Boston and the